SCYNEXISSCYX
Market Cap: $61.7M
About: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Employees: 29
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
381% more call options, than puts
Call options by funds: $77K | Put options by funds: $16K
22% more capital invested
Capital invested by funds: $22.7M [Q1] → $27.7M (+$5.07M) [Q2]
3.39% less ownership
Funds ownership: 40.1% [Q1] → 36.71% (-3.39%) [Q2]
7% less funds holding
Funds holding: 57 [Q1] → 53 (-4) [Q2]
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Research analyst outlook
We haven’t received any recent analyst ratings for SCYX.